Samuel DePalma
Research Scientist I
Sam DePalma is a Research Scientist I in the Precision Cardiology Laboratory (PCL) of Bayer and the Broad Institute. He is currently interested in developing complex, high-throughput in vitro models of the heart using human stem cell derived cardiomyocytes to gain a better understanding of the underlying mechanisms of cardiac disease and identify new therapeutic targets to treat heart failure.
Prior to joining Bayer and the PCL, DePalma earned his Ph.D. in biomedical engineering from the University of Michigan under the guidance of Brendon Baker in the Engineered Microenvironments and Mechanobiology Lab. Here, DePalma focused on integrating biomaterials, microfabrication, quantitative image analysis, and cell and molecular biology techniques to generate mechanically tunable engineered heart tissue platforms. Using these platforms, he worked to parse how cardiomyocytes sense and respond to biophysical changes that occur within the myocardial microenvironment throughout tissue development and disease progression.
